Immunotherapy with anti-PD-1 or anti-PD-L1 antibodies has become one of the leading treatment method in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (1–4). Here, CD274 is linked to non-small cell lung carcinoma.